John S. Philo

John S. Philo

Auto-generated profile, based on publicly available information

John S. Philo

Alliance Protein Laboratories, San Diego, USA

Research Focus & Metrics

Academic Career Length

50Years (1977-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 1996 in Analytical Biochemistry
Verified
Journal Article
Closed access
JWJie Wen
Jie Wen
TATsutomu Arakawa
Tsutomu Arakawa
JPJohn S. Philo
John S. Philo

1 October 2004 in Biotechnology Progress
Verified
Journal Article
Closed access
PDF file
KTKouhei Tsumoto
Kouhei Tsumoto
MUMitsuo Umetsu
Mitsuo Umetsu
IKIzumi Kumagai
Izumi Kumagai
DEDaisuke Ejima
Daisuke Ejima
JPJohn S. Philo
John S. Philo
TATsutomu Arakawa
Tsutomu Arakawa
Recombinant proteins are often expressed in the form of insoluble inclusion bodies in bacteria. To facilitate refolding of recombinant proteins obtained from inclusion bodies, 0.1 to 1 M arginine is customarily included in solvents used for refolding the proteins by dialysis or dilution. In addition, arginine at higher concentrations, e.g., 0.5–2 M, can be used to extract active, folded proteins from insoluble pellets obtained after lysing Escherichia coli cells. Moreover, arginine increases the yield of proteins secreted to the periplasm, enhances elution of antibodies from Protein‐A columns, and stabilizes proteins during storage. All these arginine effects are apparently due to suppression of protein aggregation. Little is known, however, about the mechanism. Various effects of solvent additives on proteins have been attributed to their preferential interaction with the protein, effects on surface tension, or effects on amino acid solubility. The suppression of protein aggregation by arginine cannot be readily explained by either surface tension effects or preferential interactions. In this review we show that interactions between the guanidinium group of arginine and tryptophan side chains may be responsible for suppression of protein aggregation by arginine.

1 June 2009 in Current Pharmaceutical Biotechnology
Verified
Journal Article
Closed access
PDF file
JPJohn S. Philo
John S. Philo
TATsutomu Arakawa
Tsutomu Arakawa
Aggregation or reversible self-association of protein therapeutics can arise through a number of different mechanisms. Five common aggregation mechanisms are described and their relations to manufacturing processes to suppress and remove aggregates are discussed.



1 September 2006 in The AAPS Journal
Verified
Journal Article
Closed access
PDF file
JPJohn S. Philo
John S. Philo